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Abstract
Background Better prognostic markers are needed for
pancreatic endocrine tumors. Survivin is an apoptosis
inhibitor that is suggested to have a negative prognostic
impact in several tumor types. Contradictory data exist,
especially regarding the signiﬁcance of a nuclear versus
cytoplasmic location of survivin. The prognostic relevance
of nuclear and cytoplasmic survivin expression in pancre-
atic endocrine tumors—controlled for the tumor Ki-67
index, World Health Organization classiﬁcation, and TNM
stage—was investigated.
Methods A total of 111 patients treated at a tertiary
referral center were retrospectively evaluated. Clinical data
were gathered from medical records. Immunohistochem-
istry for survivin and Ki-67 was performed on parafﬁn-
embedded tissue. Univariate and multivariate Cox analyses
were performed.
Results Patients with tumors that had\5% survivin-posi-
tive nuclei had a mean survival of 225 months [95% conﬁ-
dence interval (CI) 168–281]. The corresponding ﬁgure for
patients with 5 to 50% survivin-positive tumor cell nuclei
was 101 months [95% CI 61–140; hazard ratio (HR) 2.4;
P\0.01) and with [50% survivin-positive nuclei
47 months (95% CI 24–71; HR 4.9; P\0.001). Nuclear
survivin expression in [50% of the tumor cells was an
independent marker of apoor prognosis (HR 5.7; P\0.01).
Cytoplasmic survivin was not a signiﬁcant prognostic factor
in the multivariate analysis (HR 0.94; P = 0.90).
Conclusions High expression of nuclear survivin is a
signiﬁcant marker of a poor prognosis in patients with a
pancreatic endocrine tumor.
Introduction
Pancreatic endocrine neoplasms are rare. They are gener-
ally less aggressive than pancreatic exocrine cancers but
can often be metastatic at diagnosis. The prognosis varies
considerably; some patients live for years with liver
metastases, whereas others rapidly succumb to progressive
disease. Better prognostic criteria are needed for more
accurate prognostic guidance for the individual patient.
Data regarding survival and prognostic factors exist
mainly from smaller series of patients, and studies often
include a mix of tumor identities, such as bronchial and
midgut carcinoids and pancreatic endocrine tumors. Some
studies have included only patients who have undergone
surgery, omitting patients with a heavy tumor burden at
diagnosis, possibly creating a selection bias. A median
survival of 38 to 104 months [1, 2] and a 5-year survival
rate of 40 to 60% [3, 4] have been reported. A World
Health Organization (WHO) classiﬁcation system [5]i s
used to divide tumors into three groups: well-differentiated
neuroendocrine tumors, well-differentiated neuroendocrine
carcinomas, and poorly differentiated neuroendocrine car-
cinomas. Ki-67 has been demonstrated to have prognostic
value using a cutoff of 2, 5, or 10% [1, 4, 6–10].
In 2006, a new tumor-node-metastasis (TNM) system
for the classiﬁcation of pancreatic endocrine tumors was
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who had undergone surgery, concluded that the classiﬁca-
tion was of prognostic value. Independently, we made
similar observations in an evaluation of 324 patients [10].
Survivin, also known as BIRC5, is a member of the
family of apoptosis inhibitors. In the cytoplasm, survivin
suppresses apoptosis [13–15], and in the nucleus it takes
part in the regulation of cell division [16, 17]. Survivin is
abundantly expressed in the fetus but rarely in adult tissues.
Most cancers express the antigen [18], which has aroused
great interest as a potential drug target for cancer treatment.
Several approaches are being investigated (e.g., immuno-
therapy, gene therapy, molecular survivin antagonists), and
clinical trials are ongoing [19, 20].
Several reports have examined the prognostic relevance
of survivin expression in various tumor types. A high
expression of nuclear survivin has been suggested to cor-
relate with a poor outcome, although results have been
somewhat contradictory. Some authors have reported a
negative prognostic impact of high nuclear survivin
expression in lung cancer and hepatocellular carcinoma
[21, 22], and others have proposed the opposite in gastric
cancers and breast cancer [23, 24]. Cytoplasmic survivin
has been suggested to be an important predictor of poor
outcome in patients with pancreatic exocrine cancer [25].
A negative prognostic value of C5% of tumor cell nuclei
expressing survivin has been suggested in a group of mixed
neuroendocrine tumors, mainly midgut carcinoids but also
including a limited number of selected pancreatic endo-
crine tumors (n = 15) [26]. This was especially true in
tumors classiﬁed as well-differentiated carcinomas, where
survivin was suggested as a better prognostic marker than
the Ki-67 index. No conﬁrming reports have been pub-
lished. No reports have focused on the prognostic value of
survivin expression in pancreatic endocrine tumors.
In this article, we investigate the prognostic relevance of
survivin in a group of 111 patients from a single institution,
with information available on the Ki-67 index, WHO
classiﬁcation, and TNM stage.
Materials and methods
Patients
Patients treated at our clinic between 1986 and 2005 were
reviewed and were included in this study if parafﬁn-embed-
ded blocks of tumor tissue were available (n = 111). Data
regarding heredity, primary tumor size, staging with com-
putedtomography(CT),surgery,endocrinesyndrome,Ki-67
index, and survival were gathered from medical records. All
details concerning the material included were registered no
earlier than 1986. Patient characteristics are summarized in
Table 1. The median follow-up was 68 months (range
4–416 months). No patients were lost to follow-up. There
was no difference in the frequency of hereditary tumor,
nonfunctioning tumor, radical surgery, poorly differentiated
carcinoma, or advanced stage tumor between the patients
included in this study and the larger unselected material.
We did, however, see a tendency toward a longer median
survival (P = 0.06) in this patient cohort [10].
Ki-67
Data regarding the proliferation marker Ki-67 were
retrieved from patient charts. When data were not avail-
able, immunohistochemistry (IHC) for Ki-67 was
Table 1 Patient characteristics
Characteristic No. %
Sex
Female 50 45
Male 61 55
Tumor type
Nonfunctioning 65 59
Insulinoma 15 13
Gastrinoma 15 13
Glucagonoma 10 9
VIPoma 5 5
Cushing 1 1
Hereditary status
Sporadic 89 80
MEN-1 21 19
VHL 1 1
Surgery of primary tumor 44 41
WHO classiﬁcation (n = 95)
Well-diff. tumor 25 26
Well-diff. carcinoma 63 66
Poorly diff. carcinoma 7 7
Stage (n = 105)
I1 3 1 2
IIa 10 10
IIb 6 6
IIIa 2 2
IIIb 15 14
IV 59 56
Referred from
Primary uptake area 58 52
External referral 53 48
Size of primary tumor (cm), median 4.6 cm (range 0.6–13.5)
Age at diagnosis (years), median 53 (range 21–86)
VIP vasoactive intestinal peptide, MEN-1 multiple endocrine neo-
plasia type 1, VHL von Hippel Lindau disease, WHO World Health
Organization, diff. differentiated
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ﬁn-embedded sections of 4 lm were used for IHC. In 14
cases, no data were attained. For antigen retrieval, sections
were pretreated with 45 minutes of pressure boiling in a
citrate buffer pH 6.0. IHC was performed using an auto-
stainer (DakoCytomation, Carpinteria, CA, USA). Sections
were incubated with an anti-Ki-67 antibody (M7240;
DakoCytomation) in antibody diluent (DakoCytomation) at
room temperature for 60 min. The reaction product was
revealed using Dako kit 50087 (DakoCytomation). Sec-
tions were counterstained with Mayer’s hematoxylin. Ini-
tial experiments were performed with omission of the
primary antibody. All sections were scored by two indi-
viduals blinded for patient outcome, according to the per-
centage of nuclear staining in the ﬁeld with the highest
percentage of staining (‘‘hot spot’’), deﬁned after assessing
the entire section (in accordance with the method applied
by Professor Lars Grimelius, Department of Genetics and
Pathology, Uppsala).
Survivin
Sections were deparafﬁnized and pretreated in TRS buffer,
pH 6.0 (S1699; DakoCytomation), in a pressure cooker
(Biocare Medical, Concorde, CA, USA). The staining pro-
cedure was performed in an autostainer (Autostainer Plus;
DakoCytomation). A mouse monoclonal anti-survivin anti-
body(sc-17779;SantaCruzBiotechnology,SantaCruz,CA,
USA) was diluted to 1:50 in antibody diluent (DakoCyto-
mation) and incubated with sections for 1 h at room tem-
perature. A Dako EnVision kit (K5007; DakoCytomation)
was applied according to the manufacturer’s instructions,
and the chromogen 3,30-diaminobenzidine was applied to
reveal the complex. Mayer’s hematoxylin was used for
counterstaining. The primary antibody was omitted as the
negativecontrolininitialexperiments;andhumantonsilwas
included on a number of slides as a positive control.
Nuclear and cytoplasmic survivin expression was
assessed. All sections were scored by two of the authors
(S.E., M.H.L.) blinded for patient outcome. The parameter
was the percentage of positive cells, and results are
reported semiquantitatively as \5% (low), 5 to 50%
(medium), or [50% of cells (high). The test–retest reli-
ability results were calculated based on these initial
assessments. The two observers reevaluated slides together
when their scoring had differed.
WHO classiﬁcation
Tumors were classiﬁed into three groups according to the
WHO classiﬁcation, based on, for example, the mitotic
index and the presence of gross invasion. All cases were
reevaluated based on the existing pathology, surgery, and
radiology reports. In ambiguous cases, new pathology
assessments were performed.
TNM staging
Staging was performed according to the suggested deﬁni-
tions [11]. Stage I was deﬁned as a primary tumor conﬁned
to the pancreas and\2 cm. Stage IIa was a primary tumor
conﬁned to the pancreas and 2 to 4 cm; stage IIb was a
primary tumor [4 cm or invading the duodenum or bile
duct. Stage IIIa was deﬁned as a tumor invading adjacent
organs (stomach, spleen, colon, adrenal gland) or the wall
of large vessels (celiac axis, superior mesenteric artery).
The presence of lymph node metastases deﬁned stage IIIb
and distant metastases stage IV. Staging reﬂected the tumor
burden at diagnosis and was based on data retrieved from
medical records. All cases were reevaluated based on
existing pathology, surgery, and radiology reports. In
ambiguous cases, new pathology assessments were
performed.
Statistical analysis
Test–retest reliability in the assessment of Ki-67 and sur-
vivin was assessed using the Spearman rank correlation
test. The correlation between the two observers was 0.82
for the Ki-67 index score. For nuclear and cytoplasmic
survivin staining, it was 0.89 and 0.84, respectively. Dif-
ferences in the expression of survivin between groups of
patients were analyzed with the nonparametric Kruskal-
Wallis test.
Kaplan–Meier methodology was used to estimate sur-
vival, which was calculated as the time from diagnosis to
the last date of follow-up of patients still alive at the clo-
sure of this study or death from any cause. No patients were
lost to follow-up. The log-rank test was used to test dif-
ferences in survival.
A multivariate Cox regression model was ﬁtted to
evaluate the independent effects of nuclear survivin,
cytoplasmic survivin, and the Ki-67 index, with informa-
tion on the WHO classiﬁcation and TNM stage. Only 84
patients were included in this analysis owing to a missing
Ki-67 index and/or WHO classiﬁcation data in the
remaining cases. Univariate subanalyses of patients with a
well-differentiated tumor, well-differentiated carcinoma, or
poorly differentiated carcinoma, respectively, were per-
formed, as was a multivariate analysis of patients with a
well-differentiated carcinoma. The proportional hazards
assumption was assessed with a graphic approach. All
multivariate analyses were controlled for patient age at
diagnosis. A value of P\0.05 was considered signiﬁcant.
Statistical analyses were performed with the SPSS statis-
tical package (version 15.0).
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Results
Survivin expression
The frequency of nuclear and cytoplasmic survivin expres-
sion is summarized in Table 2. Most patients (72%) had
\5% survivin-positive nuclei in their tumors, 19% had 5 to
50, and 9% had [50% positive nuclei (Fig. 1a). The fre-
quency of survivin-positive cytoplasm was higher: 35% had
\5, 9% had 5 to 50%, and 56% had[50% survivin-positive
cytoplasm(Fig. 1b).Therewasasigniﬁcantdifferenceinthe
expression of nuclear and cytoplasmic survivin between
well-differentiated tumors, well-differentiated carcinomas,
and poorly differentiated carcinomas, with nuclear survivin
being the mostabundant inpoorly differentiated carcinomas
(P\0.01),andcytoplasmicsurvivinmorehighlyexpressed
in well-differentiated tumors (P\0.01).
There was no signiﬁcant difference in the expression of
nuclear or cytoplasmic survivin between patients with
functioning or nonfunctioning tumors. Tumors from
patients with nonfamilial disease had a higher nuclear
survivin presence (P = 0.04) compared to tumors from
patients with multiple endocrine neoplasia type 1 (MEN-1),
whereas there was a trend toward MEN-1 tumors having a
higher cytoplasmic survivin presence (P = 0.08). How-
ever, when stratiﬁed according to the WHO classiﬁcation,
there were no differences in the expression of nuclear or
cytoplasmic survivin between patients with sporadic or
MEN-1-related tumors.
Univariate survival analysis
The presence of nuclear survivin was a negative prognostic
factor in the univariate analysis (Fig. 2). Patients with\5%
positive nuclei had a median survival of 225 months
[95% conﬁdence interval (CI) 168–281]; the corresponding
ﬁgure for patients with 5 to 50% positive nuclei was
101 months (95% CI 61–140; hazard ratio (HR) 2.4; P\
0.01], and for patients with [50% positive nuclei it was
47 months (95% CI 24–71; HR 4.9; P\0.001).
There was no signiﬁcant difference in survival in a
three-way comparison of patients with low, medium, or
high cytoplasmic survivin (P = 0.22). However, when
dichotomizing patients at more or less than 5% cytoplasmic
survivin, there was a tendency toward a longer survival in
patients with high cytoplasmic survivin (P = 0.084)
(Fig. 3). Patients with low cytoplasmic survivin lived a
mean of 105 months from diagnosis (95% CI 73–137),
whereas patients with medium or high cytoplasmic survi-
vin lived for 181 months (95% CI 128–233). Thus, cyto-
plasmic survivin was certainly not a negative prognostic
factor; rather, there was a tendency toward it being a
positive prognostic marker.
Patients with a higher nuclear than cytoplasmic survivin
score had a signiﬁcantly shorter survival (50 months, 95%
CI 29–72) compared to patients with a higher cytoplasmic
than nuclear survivin score (218 months, 95% CI 157–280)
or an even distribution (115 months, 95% CI 80–151)
(P\0.001).
No patient with a well-differentiated tumor had high
nuclear survivin expression ([50%), and we found no
difference in survival between patients with a low or
medium nuclear survivin in this tumor group. Among well-
differentiated carcinomas, nuclear survivin was a border-
line signiﬁcant prognostic marker in the univariate analysis
(P = 0.05). Patients with\5% positive nuclei had a mean
survival of 140 months (95% CI 108–172). The corre-
sponding ﬁgure for patients with 5 to 50% positive nuclei
was 103 months (95% CI 64–141), and for patients with
[50% positive nuclei it was 51 months (95% CI 19–83).
There was no signiﬁcant difference in survival in this group
between patients with more or less than 5% cytoplasmic
survivin.
Table 2 Survivin
immunoreactivity in pancreatic
endocrine tumors (n = 111)
Total all specimens
immunostained for survivin
(n = 111). Well-differentiated
tumors, Well-differentiated
carcinomas, Poorly
differentiated carcinomas:
number of specimens
immunostained for survivin
when the WHO classiﬁcation
was available (n = 95)
Immunoreactivity No. of patients
Total Well-differentiated
tumors
Well-differentiated
carcinomas
Poorly differentiated
carcinomas
Nuclear survivin
\5% 80 (72%) 23 (92%) 44 (70%) 2 (29%)
5–50% 21 (19%) 2 (8%) 12 (19%) 3 (43%)
[50% 10 (9%) – 7 (11%) 2 (29%)
Cytoplasmic survivin
\5% 39 (35%) 4 (16%) 28 (44%) 3 (43%)
5–50% 10 (9%) — 6 (10%) 1 (14%)
[50% 62 (56%) 21 (84%) 29 (46%) 3 (33%)
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a Ki-67 index C2%, having a nuclear survivin level of
[5% showed a tendency toward being a signiﬁcant nega-
tive prognostic marker (P = 0.08), and a cutoff of\50% or
[50% rendered a highly signiﬁcant difference in survival
(P\0.001) (Fig. 4). Patients with a high nuclear survivin
and a Ki-67 index C2% lived, on average, 21 months from
diagnosis (95% CI 14–29), whereas the corresponding
ﬁgure for patients with a low or medium nuclear survivin
level was 99 months (95% CI 75–123).
In patients with poorly differentiated carcinoma, a
nuclear survivin presence of \5% emerged as a positive
prognostic marker (P = 0.04). Patients with a low nuclear
survivin presence, on average, lived twice as long from
diagnosis, 40 months (95% CI 28–52), compared to
22 months (95% CI 12–31) for patients with a medium or
high nuclear survivin presence.
Fig. 1 a Pancreatic endocrine tumor with a high expression of
nuclear survivin. Dark brown immunoreactivity shows survivin-
expressing tumor cell nuclei. Surrounding ﬁbroblast cell nuclei lack
survivin and are blue. b Pancreatic endocrine tumor with a low
expression of nuclear survivin and abundant expression of cytoplas-
mic survivin, as indicated by the brown chromogen. Surrounding
ﬁbroblast cells lack survivin expression
Fig. 2 High nuclear survivin is a signiﬁcant negative predictor of
survival (P\0.001)
Fig. 3 Tendency toward cytoplasmic survivin being a positive
predictor of survival (P = 0.084)
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When controlled for the Ki-67 index, cytoplasmic survivin,
WHO classiﬁcation, and TNM stage in a multivariate
model, high nuclear survivin emerged as a signiﬁcant
negative prognostic marker with an HR of 5.7 (P\0.01).
A medium nuclear survivin presence carried an HR of 1.8
but was not signiﬁcant (P = 0.21). High cytoplasmic sur-
vivin was not a signiﬁcant prognostic factor (HR 0.94;
P = 0.90).
In a multivariate analysis that included only patients
with well-differentiated carcinoma and that evaluated
nuclear survivin, cytoplasmic survivin, and the Ki-67
index, only high nuclear survivin emerged as a signiﬁcant
prognostic marker (HR 3.8; P = 0.03).
Discussion
Predicting the prognosis for the individual cancer patient is
of paramount importance. The factors used in this tumor
group today are not satisfactory, and there is a need for
additional markers to ﬁne-tune this process. We report a
prognostic value of survivin immunohistochemistry in a
large group of patients with pancreatic endocrine tumors
treated at a single institution. A prognostic value of sur-
vivin has previously been suggested in a study of 15 pan-
creatic endocrine tumors [26]. We present conﬁrmatory
data on a more comprehensive group of 111 patients.
This was also a retrospective study, with the limitations
that it implies. A prospective conﬁrmation of our results
would of course provide a stronger foundation for clinical
application. The patients evaluated in this study constitute
a selection of all patients treated at our clinic between 1986
and 2005 based on tumor tissue availability. Although we
found no differences in tumor stage or WHO classiﬁcation
between included and not included patients, we did see a
tendency toward a longer survival among patients selected
for this study.
The assessment of survivin expression was done in a
semiquantitative manner. Although a quantitative analysis
provides more detailed data, it causes a loss of simplicity
and clinical applicability. Semiquantitative analysis of
survivin immunoreactivity is simple and straightforward,
and it can easily be used in a clinical setting, which is a
major advantage.
We found a highly signiﬁcant negative prognostic value
of nuclear survivin. Patients with low nuclear survivin
lived almost ﬁve times longer than those with high nuclear
survivin and twice as long as patients with medium high
nuclear survivin. The prognostic value of high nuclear
survivin was conﬁrmed when controlled for the WHO
classiﬁcation, TNM stage, and Ki-67 index in a multivar-
iate analysism; and it can thus be called an independent
prognostic marker. In a multivariate analysis, a Ki-67 index
of more than 2% did not signiﬁcantly affect survival time.
It thus seems that nuclear survivin is at least as good a
marker for poor prognosis as a cutoff of the Ki-67 index at
C2%. In addition, semiquantitative assessment of nuclear
survivin is relatively straightforward compared to the
tedious process of calculating a Ki-67 index.
The value of cytoplasmic survivin expression was less
clear. We did see a tendency toward patients with a low
cytoplasmic survivin having a shorter survival. Although
this was not signiﬁcant and did not persist in the multi-
variate analysis, it is an interesting ﬁnding. We also found
that patients with a predominantly cytoplasmic survivin do
much better than patients with predominantly nuclear sur-
vivin. The former lived, on average, four times longer from
the time of the diagnosis. Thus, it seems less favorable to
have survivin in the tumor cell nuclei than in the cyto-
plasm. The reason for this is not entirely clear. Different
functions of survivin in the nucleus and cytoplasm have
been suggested, and different splice variants of survivin are
known to locate in different subcellular compartments [27–
29]. It has been suggested that alternative survivin splice
variants could be more relevant for prognostication.
However, others report that these alternative splice variants
do not participate in cell division [30].
There was a marked difference in the expression of both
nuclear and cytoplasmic survivin between well-differenti-
ated tumors, well-differentiated carcinomas, and poorly
differentiated carcinomas. Well-differentiated tumors, the
group with the most favorable prognosis, in most cases had
very low nuclear and high cytoplasmic survivin. Thus, with
Fig. 4 Among patients with well-differentiated carcinoma and Ki-
67[2%, patients with a nuclear survivin [50% fared signiﬁcantly
worse
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prognostic signiﬁcance could be seen in this tumor group.
Among well-differentiated carcinomas, it is often
exceedingly difﬁcult to make an accurate prediction of
prognosis for the patients: Some patients have indolent
tumors, whereas others experience rapid tumor progres-
sion. A Ki-67 index of C2% is often cited as a negative
sign in these patients. High nuclear survivin expression was
a bit more common in this group, although tumors with low
survivin still dominated. High nuclear survivin was an
independent sign of a poor prognosis: When looking only
at patients with well-differentiated carcinoma and a Ki-67
index of C2%, there was a marked, almost ﬁvefold, dif-
ference in survival from time of diagnosis between patients
with a nuclear survivin level over or under 50% (Fig. 4).
Thus, nuclear survivin could have important prognostic
implications in the subgroup of patients with well-differ-
entiated carcinoma and a Ki-67 index of C2%. Patients
with low or medium nuclear survivin did indeed have a
lower mean Ki-67 index (Table 3). However, because the
standard deviation of the Ki-67 index was so great, pre-
diction based on this marker is difﬁcult; thus, nuclear
survivin could be an important additional marker helping to
predict survival and decisions regarding the treatment
approach.
Poorly differentiated carcinomas are aggressive cancers
with a generally poor prognosis. However, even in this
group survival varies, and some patients fare notably better
than others. In this study, we found a doubled survival time
in patients with low nuclear survivin compared to patients
with medium or high survivin. Although survival is still
relatively short, this is a marked difference with potentially
important consequences for the individual patients.
Grabowski et al. suggested a prognostic value of nuclear
survivin in material consisting of different types of neu-
roendocrine gastrointestinal tumors [26]. Our data support
their observations and unequivocally demonstrate a prog-
nostic value of nuclear survivin in pancreatic endocrine
tumors. This was especially true for patients with well-
differentiated carcinoma, where a prognosis is notoriously
difﬁcult to predict. Being relatively simple to evaluate and
adding signiﬁcant prognostic value, survivin could prove
an important addition to the limited arsenal of tools
available for prognostic guidance in these patients. We
hope to see further conﬁrmatory studies and subsequent
incorporation of survivin evaluation in the clinical routine
for these patients.
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